Surveillance of Ocular Surface Flora (SURFACE)

Topical fluoroquinolones (FQs) have achieved widespread use in ophthalmology for both the treatment and prophylaxis of ocular infections. The present study is set to determine the bacteria present on the ocular surface in patients at the time of cataract surgery and to assess the rate of resistance of ocular isolates to commonly used topical antibiotics.

Arms, Groups and Cohorts in this Clinical Trial

• : A

Primary Measures

• In-vitro time Antibiotic potency
  • Time Frame: Baseline Specimen
    Safety Issue?: No

Secondary Measures

• In-vitro time to bacteria eradication
  • Time Frame: Baseline Specimen
    Safety Issue?: No

Inclusion Criteria:

• Male or female aged 55 or older
• Scheduled to undergo cataract surgery
• Able to provide written informed consent

Exclusion Criteria:

• NSAID in the eye to be swabbed within the past 30 days
• Topical anesthetic, topical antibiotic or antiseptic, or dilating drops in the eye to the swabbed within the past 7 days
• Over-the-counter artificial tear drops or astringent /redness reliever drops (e.g., Visine®, Clear eyes® in the eye to be swabbed on the day of trial
• History of conjunctivitis or any ocular infection within the past 3 months

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 50 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Allergan Industry

Overall Clinical Trial Officials and Contacts

Medical Director Study Director Allergan  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00621933

Study ID Number: MA-Zymar-08-001

ClinicalTrials.gov Identifier: NCT00621933

Health Authority: United States: Institutional Review Board